Sorrento Therapeutics (NASDAQ:SRNE) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report issued on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

SRNE opened at $0.02 on Friday. The business’s 50-day moving average price is $0.02 and its two-hundred day moving average price is $0.05. Sorrento Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.42.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.